What is Viking Therapeutics's change in other assets?

Viking Therapeutics (VKTX) reported change in other assets of -$4.63M in Q1 2026.

How has Viking Therapeutics's change in other assets changed year-over-year?

Viking Therapeutics's change in other assets decreased by 148.4% year-over-year, from $9.55M to -$4.63M.

What does change in other assets mean?

Change in miscellaneous assets affecting operating cash flow.

Viking Therapeutics VKTX Change in Other Assets

Change in Other Assets at other companies

Eli LillyLLY

$1.65B+98.4%

PfizerPFE

-$322.25M+61.9%

AmgenAMGN

-$8M-104%

Madrigal Pharmaceuticals, Inc.MDGL

$40.65M+330%

Crinetics PharmaceuticalsCRNX

$7.02M+1.5%

BioMarin PharmaceuticalsBMRN

-$1.48M-191%

Other financials

Income statement

See full

Revenue-—

Operating income-$164.1M-196%

Net income-$158.3M-247%

EPS (diluted)-$1.37-234%

Balance sheet

See full

Cash & equivalents$118.1M+211%

Total debt$137.0K-87.8%

Total equity$501.9M-40.7%

Total assets$608.2M-29.8%

Cash flow

See full

Operating cash flow-$114.0M-118%

Valuation

See full

Market cap$4.04B+38.7%

Returns & leverage

See full

Return on equity-70%-94.5pp

Debt / equity0×0.0×

Current ratio5.7×-38.5×

Where this comes from

Reported directly by Viking Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets.

The official record: Viking Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Viking Therapeutics's change in other assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Viking Therapeutics's change in other assets?: Viking Therapeutics (VKTX) reported change in other assets of -$4.63M in Q1 2026.
How has Viking Therapeutics's change in other assets changed year-over-year?: Viking Therapeutics's change in other assets decreased by 148.4% year-over-year, from $9.55M to -$4.63M.
What does change in other assets mean?: Change in miscellaneous assets affecting operating cash flow.